Price
$9.48
Decreased by -3.76%
Dollar Volume
8.96 M
ADR%
6.35
Earnings Report Date (estimate)
Feb 14, 23 (-0.35)
Market Cap.
1.36 B
Shares Float
98.23 M
Shares Outstanding
143.01 M
Beta
1.10
Price / Earnings
-5.83
BPR
194.88
20D Range
8.40 10.79
50D Range
6.72 10.79
200D Range
5.96 13.21
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 3, 22 -0.32
Increased by +20.00%
-0.38
Increased by +15.79%
Aug 3, 22 -0.37
Decreased by -5.71%
-0.43
Increased by +13.95%
May 4, 22 -0.44
Decreased by -51.72%
-0.46
Increased by +4.35%
Feb 15, 22 -0.43
Decreased by -30.30%
-0.45
Increased by +4.44%
Nov 3, 21 -0.40
Decreased by -48.15%
-0.42
Increased by +4.76%
Aug 4, 21 -0.35
Decreased by -34.62%
-0.43
Increased by +18.60%
May 5, 21 -0.29
Decreased by -16.00%
-0.41
Increased by +29.27%
Feb 24, 21 -0.33
Decreased by -94.12%
-0.29
Decreased by -13.79%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 47.83 M
Increased by +21.19%
-45.28 M
Increased by +19.14%
Decreased by -94.67%
Increased by +33.28%
Jun 30, 22 43.66 M
Increased by +13.39%
-52.05 M
Decreased by -5.57%
Decreased by -119.21%
Increased by +6.90%
Mar 31, 22 38.62 M
Increased by +0.46%
-62.80 M
Decreased by -54.51%
Decreased by -162.60%
Decreased by -53.80%
Dec 31, 21 37.93 M
Increased by +25.66%
-61.34 M
Decreased by -37.62%
Decreased by -161.71%
Decreased by -9.52%
Sep 30, 21 39.47 M
Increased by +50.07%
-56.00 M
Decreased by -52.50%
Decreased by -141.89%
Decreased by -1.62%
Jun 30, 21 38.51 M
Increased by +83.46%
-49.30 M
Decreased by -47.01%
Decreased by -128.04%
Increased by +19.87%
Mar 31, 21 38.44 M
Increased by +83.85%
-40.64 M
Decreased by -29.42%
Decreased by -105.72%
Increased by +29.60%
Dec 31, 20 30.18 M
Increased by +24.69%
-44.57 M
Decreased by -116.24%
Decreased by -147.66%
Decreased by -73.43%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.